Flexion Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 13th Annual Needham Healthcare Conference. Dr. Clayman's presentation is scheduled for April 9, 2014, at 1:40 p.m. Eastern Time. The conference will take place April 8-9, 2014, at The Westin New York Grand Central.
Flexion Reports Year-End 2013 Financial Results
GlobeNewswire - Thu Mar 27, 7:14AM CDT
- Strong cash position bolstered with additional $75 million from IPO -
Flexion Therapeutics to Report Year-End 2013 Earning Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:00PM CDT
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its year-end 2013 financial results on Thursday, March 27, 2014, at 4 p.m. ET.
Flexion Therapeutics to Present at the 34th Annual Cowen Health Care Conference
GlobeNewswire - Wed Feb 26, 8:22AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 34 Annual Cowen Health Care Conference. Dr. Clayman's presentation is scheduled for March 3, 2014, at 4:50 p.m. Eastern Time. The Conference will take place March 3-5, 2014, at The Boston Marriott Copley Place.
Flexion Therapeutics reports IPO of 5.75m shares of common stock, including underwriters' option
M2 - Wed Feb 19, 5:14AM CST
Pharmaceutical company Flexion Therapeutics Inc (NasdaqGM:FLXN) said on Tuesday that it has completed the initial public offering of 5,750,000 shares of its common stock.
Flexion Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Feb 18, 4:00PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the closing of its initial public offering of 5,750,000 shares of its common stock at an initial public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock. Flexion offered all of the shares of common stock. The aggregate net proceeds to Flexion, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67.3 million.
Talmer, Eagle Pharma, Flexion up in trading debuts
AP - Wed Feb 12, 10:17AM CST
NEW YORK (AP) — Three companies, a bank and two drug developers, making their market debuts are trading higher on Wednesday on the Nasdaq.
Flexion Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Tue Feb 11, 5:03PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $13.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "FLXN" on February 12, 2014. Flexion is offering all of the shares of common stock. Flexion has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. The offering is expected to close on February 18, 2014, subject to customary closing conditions.